Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Account Payables (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Change in Account Payables for 7 consecutive years, with -$5.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 14.15% to -$5.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.7 million, a 15.05% increase, with the full-year FY2025 number at -$6.7 million, up 15.05% from a year prior.
  • Change in Account Payables was -$5.2 million for Q4 2025 at Iovance Biotherapeutics, down from -$4.4 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $14.4 million in Q3 2024 to a low of -$10.4 million in Q2 2024.
  • A 3-year average of -$806166.7 and a median of -$2.1 million in 2023 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 247.82% in 2024; the steepest drop was 7216.44% in 2024.
  • Iovance Biotherapeutics' Change in Account Payables stood at $11.4 million in 2023, then plummeted by 153.16% to -$6.1 million in 2024, then rose by 14.15% to -$5.2 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Change in Account Payables are -$5.2 million (Q4 2025), -$4.4 million (Q3 2025), and $893000.0 (Q2 2025).